TY - T1的预处理行为和随后的治疗效果在儿童失神癫痫JF -神经学乔-神经病学SP - 1698 LP - 1706 - 10.1212 / WNL。首页0000000000004514六世- 89 - 16盟露丝c Shinnar AU -什洛莫Shinnar盟Avital克纳安非盟-佩吉·克拉克AU -丹尼斯Dlugos盟-黛博拉·g·Hirtz AU -凤鸣胡锦涛盟春燕刘盟-大卫Masur盟格劳瑟-埃里卡·维斯盟特雷西·a . AU -儿童失神癫痫的研究小组Y1 - 2017/10/17 UR - //www.ez-admanager.com/content/89/16/1698.abstract N2 -目的:描述预处理行为问题和微分作用的初始治疗儿童失神癫痫患儿(CAE)。首页方法:对儿童行为检查表(很高)管理基线,16 - 20周,和12月访问的随机双盲试验乙琥胺,拉莫三嗪、丙戊酸钠。总分数是主要的结果测量标准的问题。结果:共有382名参与者在基线,310名参与者在本周访问16 - 20日,168名参与者在12月开始的数据访问。在基线,8%(95%可信区间[CI] 6% - -11%)的儿童与CAE升高总得分(平均52.9±10.91)问题。在16 - 20周,参与者服用丙戊酸有明显高于总问题(51.7 (98.3% CI 48.6 - -54.7)),外化问题(51.4 (98.3% CI 48.5 - -54.3)),注意力问题(57.8 (98.3% CI 55.6 - -60.0)),和注意缺陷/多动问题(55.8 (98.3% CI 54.1 - -57.6))的分数相比,参与者乙琥胺(46.5 (98.3% CI 43.4 - -49.6);45.8 (98.3% CI 42.9 - -48.7);54.6 (98.3% CI 52.4 - -56.9);53.0 (98.3% CI 51.3 - -54.8))。缺乏没收自由和高周-康纳连续与严重的总问题相关的性能测试信心指数分数。 At month 12, participants taking valproic acid had significantly higher attention problems scores (57.9 [98.3% CI 55.6–60.3]) compared to participants taking ethosuximide (54.5 [95% CI 52.1–56.9]).Conclusions: Pretreatment and ongoing behavioral problems exist in CAE. Valproic acid is associated with worse behavioral outcomes than ethosuximide or lamotrigine, further reinforcing ethosuximide as the preferred initial therapy for CAE.Clinicaltrials.gov identifier: NCT00088452.Classification of evidence: This study provides Class II evidence that for children with CAE, valproic acid is associated with worse behavioral outcomes than ethosuximide or lamotrigine.ANCOVA=analysis of covariance; ANOVA=analysis of variance; CAE=childhood absence epilepsy; CBCL=Child Behavior Checklist; CI=confidence interval; CPT=Continuous Performance Test; DSM=Diagnostic and Statistical Manual of Mental Disorders; RCT=randomized controlled trial ER -